FMNL3 and ovarian cancer: Exosome‐transmitted hsa_circ_0014235 promotes NSCLC cell resistance to cisplatin by regulating the miR‐520a‐5p/CDK4 axis.[144] Luo and Gui suggest that circFoxp1 is an oncogene that confers ovarian cancer resistance to cisplatin by targeting miR‐22 and miR150‐3p to upregulate the expression of CEBPG (CCAAT enhancer binding protein gamma) and FMNL3 (formin like 3).[145] The upregulation of circFoxp1 in serum exosomes from ovarian cancer patients may serve as an independent factor for predicting adverse survival outcome and drug resistance.